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Summary There is a subclinical activation of coagulation and fibrinolysis system in
lung cancer. Alterations in hemostatic system are seen frequently in lung cancer
correlated with the prognosis of disease. In this prospective study, our purpose was to
investigate the prognostic significance of hemostatic markers in patients with lung
cancer. The study comprised 58 patients (22 squamous cell carcinoma, 16
adenocarcinoma, 20 small cell carcinoma). There were 55 men (95%)and 3 women
(5%) with a mean age of 61 years range (36–74). Plasma level of platelets (PLT),
prothrombin time (PT), active partial thromboplastin time (aPTT), antithrombin III
(AT III), fibrinogen (F) and D-dimer level were measured before the initiation of any
therapy. Patients were followed up for 17 (12–20) months. The median survival was
determined as 6.4 months. Three histopathologic groups; squamous cell carcinoma,
adenocarcinoma and small cell carcinoma were compared for the hemostatic
parameters. There were no statistically significant differences among the histo-
pathologic types for any of the parameters ðP40:05Þ: Patients were divided into two
groups as patients without distant metastasis (stages I,II,III) and with distant
metastasis (stage IV). The group with distant metastasis had higher level of D-dimer
than the other group ðPo0:05Þ: However, there were no statistically significant
differences for D-dimer level between stages IIIB and IV ðP40:05Þ: Patients having
high D-dimer and low AT III level had poor survival in our study. Thus, high level of D-
dimer and low AT III level were determined as correlated with short survival ðPo0:05Þ:
These results suggest that elevated plasma level of D-dimer and low AT III level might
be a sign of poor prognosis in patients with lung cancer.
& 2003 Published by Elsevier Ltd.
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Introduction
There is a subclinical activation of coagulation and
fibrinolysis system in cancer patients.1 Hemostatic
alterations are seen frequently in patients with
lung cancer and the degree of coagulation and
fibrinolysis activation has been found correlated
with the clinical progression of the disease.2 Tumor
cells release either coagulation factors directly
leading to coagulation pathway and thrombin
formation or plasminogen activators directly acti-
vating the fibrinolytic system.3,4 Thrombin leads to
fibrin formation which acts as a growth factor for
tumor cells and facilitates tumor angiogenesis.
Fibrin deposition in cancer tissues serves as a
barrier against the inflammatory cells that might
destroy the tumor. Also, plasminogen activators
generate plasmin which is an active serine protease
of fibrinolysis. Plasmin promotes both tumor inva-
sion and detachment of tumor cells into the
circulating channels.5,6
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In this prospective study, our purpose was to
determine whether the hemostatic parameters are
related to the histopathogical types, pretherapeu-
tic tumor stages and prognosis in lung cancer.
Patients and methods
Patients
This prospective study included 58 patients with
lung cancer. Diagnosis was performed by biopsies or
cytological specimens taken at bronchoscopy,
transthoracic needle aspiration or from surgical
specimens. The types of tumors were grouped
according to the World Health Organization Classi-
fication.7 Patients having coagulation disturbances
of other causes or taking oral anticoagulant therapy
or with malignancies other than lung cancer were
not included into the study.
In our study, 22 patients were diagnosed squa-
mous cell carcinoma, 16 patients adenocarcinoma
and 20 patients were diagnosed as small cell
carcinoma. The group consisted of 55 men (95%)
and three women (5%) with a mean age of 61 years
range (36–74). Conventional radiographs, compu-
terized tomography scanning, ultrasonography,
gallium scintigraphy and bronchoscopic examina-
tion were performed for tumor staging based on the
new international staging system.8 There were
three patients with stage IB, one patient with
stage IIA, four patients with stage IIB, six patients
with stage IIIA, 18 patients with stage IIIB and 26
patients with stage IV. Follow-up programs con-
sisted of clinical, laboratory and radiological
reassessments performed at 3–4 week intervals.
Most of the patients received either chemotherapy
(including platin regimens) or radiotherapy treat-
ment. Only five patients received semptomatic
therapy. The status of the patients who abandoned
the follow-up program was informed by telephone
interview with the patient or the family.
Methods
Before the treatment plasma was removed after
the centrifugation of venous blood samples and five
parameters; platelets (PLT), prothrombin (PT),
active partial thromboplastin time (aPTT), D-dimer
and fibrinogen (F) were all measured immediately
except for antithrombin III (AT III). Blood samples
were stored at 201C until AT III analysis. Platelet
counts were analyzed by automated complete
blood cell counting devices on ethylenediamine
tetra-acetic (EDTA) anticoagulated blood. Other
parameters were measured by the BCS System, a
high-speed random access analyzer (Dade Behring).
PT, aPTT, F, D-dimer, AT III were all measured using
commercially available reagent provided by Dade
Behring. Thrombosel-S was used for PT measure-
ment, prothrombin SL was used for the measure-
ment of aPTT. Fibrinogen was determined by the
Clauss method and Multitren U was used as a
reagent. Plasma level of D-dimer was measured by
using a latex enhanced turbidimetric test. AT III
analysis was performed by using a chromogenic
substrate and AT III concentration was assayed by
the measurement of the color.
Statistical analysis
All statistical analyses were performed using the
SPSS for windows release 9.0 package program. The
results of PLT, PT, aPTT, D-dimer and AT III were
reported as mean values 7 standard deviation
(SD). The correlation between the parameters and
three histologic groups was evaluated by Kruskal–
Wallis one-way analysis. The differences between
patients without distant metastasis (stages I–II–III)
and patients with distant metastasis (stage IV) for
the variables were evaluated by Student’s t-test.
Multivariate survival analysis was performed using
the Cox’s regression model and survival curves were
computed according to the method of Kaplan–
Meier. A value of Po0:05 was accepted as statisti-
cally significant.
Results
Patients were followed up for 17 (12–20) months.
The median survival was determined as 6.4 months.
The reference value of each parameter is given in
Table 1.
Comparison by histopathological types and
tumor stages
Three histologic groups; squamous cell carcinoma,
adenocarcinoma and small cell carcinoma were
compared for the hemostatic parameters. There
were no statistically significant differences among
the histopathologic types for any of the parameters
ðP40:05Þ: The correlation between the histological
types and hemostatic parameters is shown in
Table 1.
Patients were grouped into two categories as
having distant metastasis (stage IV) and patients
without distant metastasis (stages I–II–III). Only
plasma D-dimer level was significantly higher in
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patients with distant metastasis than the other
group ðPo0:05Þ: Other parameters did not show any
significant differences among the tumor stage
(Table 2). Also, we compared stages IIIB and IV
patients which are defined as extensive disease.
There were no significant differences for the
parameters between stages IIIB and IV ðP40:05Þ:
However, stages I, II and III were not compared
since the number of the patients was not enough
for the statistical analysis.
Comparison by the survival of patients
Multivariate survival analysis was performed using
the Cox’s regression model. Other prognostic
factors as age, sex, stage, histologic type, weight
loss and ECOG performance status were all deter-
mined (Table 3). High plasma level of D-dimer
showed a significant correlation with the short
survival as median survival¼ 9.61 months for D-
dimer o375 mg/l versus median survival¼ 2.90
months for D-dimer 4375 mg/l (95% confidence
interval (Cl) 8.06–11.16 and 95% Cl 2.20–3.61,
respectively, P¼ 0.000). Also low level of AT III was
significantly correlated with the short survival as
median survival 4.07 months for AT IIIo 75% versus
median survival 7.98 months for AT IIIX75% (95% Cl
1.75–6.40 and 95% Cl 6.54–9.43 respectively,
P ¼ 0:03) (Figs. 1 and 2). Other parameters
included PLT, PT, aPTT, F all were not determined
as predictors of survival (P40.05). Only elevated D-
dimer level and low AT III level were determined as
a sign of poor prognosis in lung cancer (Table 4).
Discussion
Numerous studies have demonstrated the tendency
of coagulation and fibrinolysis disorders to develop
in cancer patients.9,10 Basic hemostatic markers
including PLT, PT, aPTT, F, D-dimer, AT III are found
elevated in patients with lung cancer.11,12
In NSCLC and SCLC the mechanisms activating
coagulation and fibrinolysis systems are different.6
In SCLC tumor cells release tissue factor directly
activating the coagulation system. However in
NSCLC the host macrophages release procoagulant
factors which activate the fibrinolysis system.6,13
There are some studies having different results
about the correlation between the histopathologi-
cal types and hemostatic parameters.2,10 In our
study, we did not find statistically significant
differences for any parameters between three
histopathological types. Although Hagedorn et al.
reported more extensive degree of clotting ab-
normalities in patients with adenocarcinoma and
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Table 2 Comparison between patients without distant metastasis (stages I–II–III) and patients having distant
metastasis (stage IV) for the hemostatic parameters.
Parameters Stages I–II–III Stage IV P
PLT 390.717150.35 350.87116.39 0.272
PT 11.9571.3 12.9372.98 0.101
aPTT 31.5474.48 33.1275.86 0.251
F 5.872.15 5.8771.88 0.893
D-dimer 285.67180.59 375.867160.48 0.04n
AT III 105.33718.16 98.65720.3 0.192
nPo0.05 is statistically significant.
Table 1 Reference values of the variables and the correlation between the parameters and histopathological
groups.
Parameters Reference values Squamous cell carcinoma Adenocarcinoma Small cell carcinom P-value
PLT 150–400 103/mm3 4107140.6 355.77136.26 339.557114.84 0.179
PT 10–15 s 12.4171.21 12.1471.56 12.6373.38 0.714
aPTT 25–45 s 33.3574.65 31.3273.52 31.876.68 0.732
F 1.8–3.5 g/l 5.8272.12 5.7271.90 5.9472.02 0.788
D-dimer 125–375 mg/l 320.417171.72 340.657157.71 320.497202.59 0.867
AT III 75–125% 99.32721.42 102.14720.82 106.66716.93 0.314
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squamous cell carcinoma, Seitz et al. found no
significant differences between NSCLC and SCLC
patients for the hemostatic markers.2,14
In most of studies2,10 although hemostatic para-
meters do not show correlation with the histo-
pathological types it is reported that there is a
significant correlation between the parameters and
tumor stage.2 Clinical and experimental evidence
supports the idea that activation of coagulation and
fibrinolysis system plays an important role in tumor
spreading.4,15 In our study, we found only D-dimer
level significantly elevated in patients with distant
metastasis independently from the histological
type. Also there are some studies supporting our
result in which high D-dimer level was found in
patients having distant metastasis.2,10 However, in
our study, we did not find any significant differ-
ences between stages IIIB and IV for D-dimer level.
So, we conclude that D-dimer level is found
elevated in extensive disease with local or distant
metastasis.
In most of the studies it is reported that lung
cancer patients having high D-dimer level have
poor prognosis.11,16,17 Taguchi et al. found D-dimer
to be an independent predictor of survival in
patients with lung cancer.16 Similar to the previous
studies,16,17 we also performed multivariate survi-
val analysis to determine the prognostic signifi-
cance of hemostatic parameters and we found D-
dimer level higher in patients having short survival.
Pedersen et al. reported thrombocytosis as corre-
lated with the poor survival18. Thrombocytosis was
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Table 3 Characteristics of the patients in the
study.
Histologic groups
Squamous cell carcinoma 22 38%
Adenocarcinoma 16 28%
Small cell carcinoma 20 34%
TNM Stage
Stage IB 3 5%
Stage IIA 1 2%
Stage IIB 4 7%
Stage IIIA 6 10%
Stage IIIB 18 31%
Stage IV 26 45%
Male 55 95%
Female 3 5%
ECOG PS 0–2 37 64%
3–4 21 36%
Age o70 8 14%
470 50 86%
Weight loss 410% 31 53%
o10% 27 47%
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Figure. 1 Survival analysis of patients with lung cancer based on plasma level of D-dimer.
Table 4 Multivariate survival analysis with high
levels of PLT, PT, aPTT, F and D-dimer and low AT III
level.
Parameters Relative risk
estimates
P-value
PLT 4400 103/mm3 0.961 0.893
PT 415 s 1.463 0.529
aPTT 445 s 0.659 0.681
F 4 3.5 g/l 1.276 0.392
D-dimer 4375 mg/l 10.946 0.000n
AT III o75% 2.709 0.039n
nPo0.05 is statistically significant.
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reported as being associated with the tumor load.
In our study, thrombocytosis was not found as
predicting prognosis. Also other parameters includ-
ing PT, aPTT and F all did not show statistically
significant correlation with the survival.
In lung cancer, the synthesis of anticoagulant
proteins decrease and in cancer patients with
distant metastases the serum level of AT III
reduces.19 There is only a few number of studies
investigating the prognostic significance of AT III
level. Bucheri et al. had reported 36% of their
patients having reduced AT III level but low level of
AT III was not determined as predicting poor
prognosis.11 Kemkes et al. found AT III level normal
in patients with lung cancer.20 In our study, we also
investigated the prognostic significance of AT III
level in lung cancer, and we found short survival in
patients with low level of AT III. Further studies are
needed to investigate the prognostic significance of
low AT III level in lung cancer.
As a conclusion, patients with lung cancer mostly
have hemostatic abnormalities which worsen with
the progression of disease. Thus in lung cancer high
level of D-dimer and low AT III level are correlated
with short survival predicting poor prognosis in-
dependently from the histopathological type and
tumor stage.
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